Novartis division Sandoz to set up Global Capability Centre in Hyderabad MD Bureau1 Feb 2023 8:00 AM GMTThe centre will initially have a workforce of 800 employees, with plans to increase to approximately 1,800 people in the near future.
Operating profit to grow again ahead of Sandoz spin off: Novartis Ruchika Sharma1 Feb 2023 4:30 AM GMTNovartis said in its statement it's on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its...
Interim relief to Novartis: Delhi HC reinstates Entresto (Sacubitril-Valsartan) patent in India Farhat Nasim27 Jan 2023 12:56 PM GMTDelhi: In an interim relief to Swiss pharma major Novartis, the Delhi High Court has reinstated Entresto (sacubitril/valsartan) patent in India amid...
Novartis gets European Commission nod for Pluvicto to treat progressive PSMA-positive metastatic castration-resistant prostate cancer Ruchika Sharma17 Jan 2023 10:00 AM GMTPluvicto is an intravenous radioligand therapy combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in...
EMA seeks to issue guidance on liver damage from Novartis gene therapy Zolgensma Ruchika Sharma15 Jan 2023 6:45 AM GMTThe drug won conditional EU approval during early 2020 and it costs more than $2 million per patient
Novartis in tight spot as HC stays grant of patent for Entresto amid generics fight Farhat Nasim13 Jan 2023 6:29 AM GMTNew Delhi: Amid the earlier patent of blockbuster heart failure drug Entresto expiring on January 16, 2023 concerns rise for the Swiss multinational...
Novartis gets CDSCO Panel nod to market anticancer drug Trametinib and Dabrafenib for additional indication Medical Dialogues Team1 Jan 2023 12:15 PM GMTNew Delhi: In a significant development, the drug major Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the...
Accused of trying to delay in launch of Hypertension drug generic, Novartis settles litigation with payment of Rs 2028 crore Ruchika Sharma29 Dec 2022 8:45 AM GMTNovartis and Par were accused of entering an illegal "reverse payment" agreement to delay launches of less expensive, generic versions of Exforge,...
Novartis gets CDSCO panel nod to study anticancer drug JDQ443 Medical Dialogues Team17 Dec 2022 12:30 PM GMTNew Delhi: Pharmaceutical major Novartis, has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Novartis prostate cancer therapy Pluvicto bags European Commission nod Ruchika Sharma14 Dec 2022 10:45 AM GMT"The approval of Pluvicto by the European Commission marks a major milestone for patients with advanced prostate cancer who have few alternative...
JB Pharma slashes price of critical Heart Failure medicine AZMARDA (Sacubitril-Valsartan) by nearly 50 percent Ruchika Sharma5 Dec 2022 9:07 AM GMT"This move by JB will not only help reduce the cost of treatment but will also help enhance the productive years of patients and their quality of...
Sandoz, Teva Pharma plans to ramp up biosimilars production Ruchika Sharma23 Nov 2022 8:00 AM GMTTeva Chief Executive KÃ¥re Schultz said the company was targeting "80% of what's going off-patent in the next 10 years" including big sellers like the...
